Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab

Gynecol Oncol. 2011 Feb;120(2):313-4. doi: 10.1016/j.ygyno.2010.10.002. Epub 2010 Nov 5.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Carcinoma, Ovarian Epithelial
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasms, Glandular and Epithelial / drug therapy
  • Ovarian Neoplasms / drug therapy
  • Rupture, Spontaneous / chemically induced
  • Urinary Bladder Diseases / chemically induced*
  • Urinary Bladder Diseases / surgery

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab